跳到正文
原文
Nature Medicine· Stephan P. Tenbaum·· 29 天前AI 评分13

作者更正:β-catenin 赋予结肠癌对 PI3K/AKT 抑制剂的耐药性

Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

AI 导读

Nature Medicine 发表更正通知,修正了第 6b 图中 T49 Xenograft 图像与图 1b 重复的错误。修正后的图像已替换为对应染色描述的代表性共聚焦图片,该通知旨在更正原文的图像错误。

正文

Correction to: Nature Medicine https://doi.org/10.1038/nm.2772, published online 20 May 2012.

In the version of the article initially published, the “T49, Xenograft” image in Fig. 6b was a duplicate of the image in Fig. 1b. A corrected version of Fig. 6b is shown below as Fig. 1, where the “T49, Xenograft” image has been replaced with a different representative confocal image corresponding to the staining described in that panel. This notice serves to amend the error.

Fig. 1

Corrected Fig. 6b.

Author information

Author notes

  1. Paloma Ordóñez-Morán

    Present address: Swiss Institute for Experimental Cancer Research, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

  2. These authors contributed equally: Stephan P. Tenbaum, Paloma Ordóñez-Morán, Isabel Puig.

Authors and Affiliations

  1. Vall d’Hebrón Institut d’Oncología (VHIO), Stem Cell and Cancer Laboratory, Barcelona, Spain

    Stephan P. Tenbaum, Isabel Puig, Irene Chicote, Oriol Arqués & Héctor G. Palmer

  2. Instituto de Investigaciones Biomédicas ‘Alberto Sols’, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain

    Paloma Ordóñez-Morán & Alberto Muñoz

  3. Department of Pathology, Hospital Universitari Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain

    Stefania Landolfi & Santiago Ramón y. Cajal

  4. Group of Drug Delivery and Targeting, Centro de Investigaciones en Bioquímica y Biología Molecular (CIBBIM)–Nanomedicine and Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Hospital Universitari Vall d’Hebrón, Institut de Recerca Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain

    Yolanda Fernández & Simó Schwartz Jr

  5. Parc de Recerca Biomèdica de Barcelona (PRBB), Centre d´Imatge Molecular (CRC) Corporació Sanitària, Barcelona, Spain

    José Raúl Herance, Juan D. Gispert & Santiago Rojas

  6. VHIO, Genomics Cancer Group, Barcelona, Spain

    Leire Mendizabal & Ana Vivancos

  7. Centre for Respiratory Research, Rayne Institute, University College London, London, UK

    Susana Aguilar

  8. Hematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, UK

    Susana Aguilar

  9. General Surgery Service, Hospital Universitari Vall d’Hebrón, Barcelona, Spain

    Eloy Espín

  10. Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts, USA

    José Baselga

  11. Howard Hughes Medical Institute, Chevy Chase, Maryland, USA

    José Baselga

  12. Medical Oncology Department, Hospital Universitari Vall d’Hebrón, Barcelona, Spain

    Josep Tabernero

Authors

  1. Stephan P. Tenbaum
  2. Paloma Ordóñez-Morán
  3. Isabel Puig
  4. Irene Chicote
  5. Oriol Arqués
  6. Stefania Landolfi
  7. Yolanda Fernández
  8. José Raúl Herance
  9. Juan D. Gispert
  10. Leire Mendizabal
  11. Susana Aguilar
  12. Santiago Ramón y. Cajal
  13. Simó Schwartz Jr
  14. Ana Vivancos
  15. Eloy Espín
  16. Santiago Rojas
  17. José Baselga
  18. Josep Tabernero
  19. Alberto Muñoz
  20. Héctor G. Palmer

Corresponding author

Correspondence to Héctor G. Palmer.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tenbaum, S.P., Ordóñez-Morán, P., Puig, I. et al. Author Correction: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med (2026). https://doi.org/10.1038/s41591-026-04750-7

Download citation

  • Published: 22 October 2026

  • Version of record: 22 October 2026

  • DOI: https://doi.org/10.1038/s41591-026-04750-7

来源:Nature Medicine · nature.com